This is a two-arm, multi-center, double-blind, randomized, placebo-controlled phase III study. A total of 60 subjects with post-COVID will be enrolled.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged ≥ 18
With post-COVID condition
Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)
Able to provide signed informed consent (by the subject or his/her legally authorized representative)
Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent
You may not be if
Neurological disorders prior to COVID-19 diagnosis
With pre-existing terminal illness
With known immune disease
Is pregnant or breastfeeding
Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening
Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period
Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases
Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters
